News Column

Studies in the Area of Nanocarriers Reported from University of California (Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly...

July 4, 2014



Studies in the Area of Nanocarriers Reported from University of California (Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm)

By a News Reporter-Staff News Editor at Health & Medicine Week -- Data detailed on Nanocarriers have been presented. According to news reporting from Santa Barbara, California, by NewsRx journalists, research stated, "Targeted nanomedicine holds promise to find clinical use in many medical areas. Endothelial cells that line the luminal surface of blood vessels represent a key target for treatment of inflammation, ischemia, thrombosis, stroke, and other neurological, cardiovascular, pulmonary, and oncological conditions."

The news correspondents obtained a quote from the research from the University of California, "In other cases, the endothelium is a barrier for tissue penetration or a victim of adverse effects. Several endothelial surface markers including peptidases (e.g., ACE, APP, and APN) and adhesion molecules (e.g., ICAM-1 and PECAM) have been identified as key targets. Binding of nanocarriers to these molecules enables drug targeting and subsequent penetration into or across the endothelium, offering therapeutic effects that are unattainable by their nontargeted counterparts. We analyze diverse aspects of endothelial nanomedicine Including (i) circulation and targeting of carriers with diverse geometries, (ii) multivalent interactions of carrier with endothelium, (iii) anchoring to multiple determinants, (iv) accessibility of binding sites and cellular response to their engagement, (v) role of cell phenotype and microenvironment in targeting, (vi) optimization of targeting by lowering carrier avidity, (vii) endocytosis of multivalent carriers via molecules not implicated in internalization of their ligands, and (viii) modulation of cellular uptake and trafficking by selection of specific epitopes on the target determinant, carrier geometry, and hydrodynamic factors."

According to the news reporters, the research concluded: "Refinement of these aspects and improving our understanding of vascular biology and pathology is likely to enable the clinical translation of vascular endothelial targeting of nanocarriers."

For more information on this research see: Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm. ACS Nano, 2014;8(5):4100-4132. ACS Nano can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Nano - www.pubs.acs.org/journal/ancac3)

Our news journalists report that additional information may be obtained by contacting M. Howard, University of California, Dept. of Chem Engn, Center Bioengn, Santa Barbara, CA 93106, United States. Additional authors for this research include B.J. Zern, A.C. Anselmo, V.V. Shuvaev, S. Mitragotri and V. Muzykantov (see also Nanocarriers).

Keywords for this news article include: Angiology, California, Endothelium, Nanocarriers, Santa Barbara, United States, Nanotechnology, Emerging Technologies, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Medicine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters